ArticleScience (New York, N.Y.)2021
Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India.
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Fear of COVID-19 Among College Students: A Systematic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern.Frontiers in public health · 2021Pooled it
- A generalized lineage nomenclature for viral genomic epidemiology.Nature microbiology · 2026Article
- SARS-CoV-2 Delta variant-specific ORF3a mutations destabilize lysosomal homeostasis to trigger lysosomal damage-mediated cell death.Communications biology · 2026Article
- Two years of SARS-CoV-2 genomic surveillance capacity development in Guinea.Scientific reports · 2026Article
- Pathological characteristics of SARS-CoV-2 variants and immune responses induced in a COVID-19 macaque model.Communications biology · 2026Article
- Determination and comparison of serum C-reactive protein levels in patients with Omicron and Delta strains of COVID-19 hospitalized in Imam Khomeini Hospital, Urmia, 2021.BMC infectious diseases · 2025Article
- From Wuhan to Omicron K.P2 strain: A comprehensive review of SARS-CoV-2 phylogeny and public health implications of the latest booster vaccine.Human vaccines & immunotherapeutics · 2025Review
- Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025Review
- A successful response to the second wave of COVID-19 in the slums of Delhi.Journal of global health · 2025Article
- Worldwide SARS-CoV-2 Omicron variant infection: Emerging sub-variants and future vaccination perspectives.Journal of the Formosan Medical Association = Taiwan yi zhi · 2025Review
- SARS-CoV-2: The Interplay Between Evolution and Host Immunity.Annual review of immunology · 2025Review
- National investment case development for pathogen genomics.Cell genomics · 2025Review
- SARS-CoV-2 Alchemy: Understanding the dynamics of age, vaccination, and geography in the evolution of SARS-CoV-2 in India.PLoS neglected tropical diseases · 2025Article
- Evaluation of potentially toxic elements and pharmaceutical compounds in leachate and exhaust air from non-incineration medical waste treatment devices.Scientific reports · 2025Article
- Leveraging dynamics informed neural networks for predictive modeling of COVID-19 spread: a hybrid SEIRV-DNNs approach.Scientific reports · 2025Article
- Study research protocol for Phenome India-CSIR Health Cohort Knowledgebase: A prospective multi-modal follow-up study on a nationwide employee cohort.Biology methods & protocols · 2025Article
- Characterization of key spike RBD residues influencing SARS-CoV-2 variant adaptation to avian ACE2.Frontiers in cellular and infection microbiology · 2025Article
- Comparing lagged impacts of mobility changes and environmental factors on COVID-19 waves in rural and urban India: A Bayesian spatiotemporal modelling study.PLOS global public health · 2025Article
- Impact of COVID-19 infection on laboratory and clinical outcomes of ovarian stimulation using antagonist protocol.Frontiers in medicine · 2025Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
80 authors.
Funding
Abstract
Delhi, the national capital of India, experienced multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks in 2020 and reached population seropositivity of >50% by 2021. During April 2021, the city became overwhelmed by COVID-19 cases and fatalities, as a new variant, B.1.617.2 (Delta), replaced B.1.1.7 (Alpha). A Bayesian model explains the growth advantage of Delta through a combination of increased transmissibility and reduced sensitivity to immune responses generated against earlier variants (median estimates: 1.5-fold greater transmissibility and 20% reduction in sensitivity). Seropositivity of an employee and family cohort increased from 42% to 87.5% between March and July 2021, with 27% reinfections, as judged by increased antibody concentration after a previous decline. The likely high transmissibility and partial evasion of immunity by the Delta variant contributed to an overwhelming surge in Delhi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.